Mechanisms that drive addiction to sugar rich foods are a major driving factor in the pathogenesis of obesity, which has become one of the most significant health care burdens. The molecular underpinnings of these hedonic mechanisms that drive addiction to sugar are poorly understood. The investigators demonstrated that methylglyoxal (MGO) derived Advanced Glycation Endproducts (AGEs) enhance food intake especially under a high sugar diet. The investigators identified a methylglyoxal (MGO) lowering cocktail, Gly-low, a combination of alpha-lipoic acid, nicotinamide, thiamine, pyridoxamine, and piperine that demonstrates a multimodal effect influencing many pathways related to aging including calorie restriction. Glycation lowering (Gly-low) treatment significantly reduces food intake and weight gain in the db/db mice that lack the leptin receptor. The investigators also extended the lifespan of C57BL/6 mice fed with these compounds starting when they were 24 months old. Based on these results, the investigators hypothesized that methylglyoxal (MGO) lowering cocktail of compounds can be given to adults with obesity, specified as body mass index (BMI) >27, to lower serum and urinary markers of insulin resistance, lower boy mass index (BMI), and lower food intake.

开始日期2024-12-01

申办/合作机构

The University of California, San Francisco

NCT05713799 / Not yet recruiting临床2期IIT

Phase II Trial of the Combination of Alpha-lipoic Acid and Mirabegron in Women and in Men With Obesity

Background:
Obesity and related illnesses cause at least 2.8 million deaths each year worldwide. Few treatments exist for obesity that are safe and widely available. A study drug (mirabegron [MG]) combined with a supplement (alpha-lipoic acid [ALA]) may help.
Objective:
To learn how MG and ALA can help the body process food.
Eligibility:
People aged 18 to 65 years with a body mass index between 30 and 40 kg/m2.
Design:
Participants will be screened. They will have a physical exam. They will have blood and urine tests and a test of their heart function. They will speak with a dietician.
The study has two phases. Each phase begins with a 2-day stay in the clinic; then the participant will take the study drugs at home for about 4 weeks, followed by another 2-day stay in the clinic. They will also have outpatient visits about 2 weeks after each clinic stay.
During the clinic stays, participants will undergo many tests:
They will have a plastic tube (catheter) inserted into a vein in each arm. These will be used to draw blood and to infuse glucose (sugar) and insulin.
They will have imaging scans.
They will have a clear hard plastic shield placed over their head to measure oxygen and carbon dioxide as they breathe.
Participants will take the study drugs at home. Both MG and ALA are taken by mouth with water. During one phase, participants will take MG plus a placebo. A placebo looks like the study drug but doesn t contain medicine.
They will log their diet, exercise, and sleep....

开始日期2024-05-01

申办/合作机构

National Institute of Diabetes & Digestive & Kidney Diseases

IRCT20230123057193N3 / Suspended临床2/3期IIT

The effect of supplementation with alpha lipoic acid on serum levels of factors, disease enzymes, lipid fractions and oxidative stress in patients with psoriasis

开始日期2024-04-13

申办/合作机构

Tehran University of Medical Sciences

100 项与硫辛酸相关的临床结果

登录后查看更多信息

100 项与硫辛酸相关的转化医学

登录后查看更多信息

100 项与硫辛酸相关的专利（医药）

登录后查看更多信息

6,594

项与硫辛酸相关的文献（医药）

2024-04-01·Materials today. Bio

Multi-targeting inulin-based nanoparticles with cannabidiol for effective prevention of ulcerative colitis.

Article

作者: Xuan Zhang ; Xia Gao ; Xiangzhou Yi ; Hui Yu ; Mingyang Shao ; Yongcheng Li ; Xuanri Shen

The pathogenesis of ulcerative colitis (UC) is closely related to severe inflammation, damaged colonic mucosal barrier, increased oxidative stress and intestinal ecological imbalance. However, due to the nonspecific distribution and poor bioavailability of drugs, UC treatment is still a serious challenge. Here, a mitochondria/colon dual targeted nanoparticles based on redox response was developed to effectively alleviate UC. Cannabidiol nanoparticles (CBD NPs) with a particle size of 143.2 ± 3.11 nm were prepared by self-assembly using polymers (TPP-IN-LA) obtained by modifying inulin with (5-carboxypentyl) triphenyl phosphonium bromide (TPP) and α-lipoic acid (α-LA). Excitingly, the constructed CBD NPs showed excellent mitochondrial targeting, with a Pearson correlation coefficient of 0.76 at 12 h. The results of animal imaging in vivo showed that CBD NPs could be effectively accumulated in colon tissue. Not only that, CBD showed significant glutathione stimulated release in the presence of 10 mM glutathione at pH 7.4. The results of in vivo animal experiments showed that CBD NPs significantly ameliorated DSS-induced colonic inflammation by modulating the TLR4-NF-κB signaling pathway. Moreover, CBD NPs significantly improved the histological damage of colon in UC mice, increased the expression level of tight junction protein ZO-1, and effectively restored the intestinal mucosal barrier function and intestinal mucosal permeability. More importantly, CBD NPs significantly improved the species composition, abundance and amount of short chain fatty acids of intestinal flora in UC mice, thus effectively maintaining the balance of intestinal flora. The dual-targeted and glutathione-responsive nanoparticles prepared in this study provide a promising idea for achieving targeted delivery of CBD for effective treatment of UC.

2024-03-01·Veterinary and animal science

Effects of feeding bergamot pulp and olive leaves on performance and meat quality in Apulo-Calabrese pigs.

Article

作者: Manuel Scerra ; Francesco Foti ; Pasquale Caparra ; Caterina Cilione ; Matteo Bognanno ; Fortugno Paolo ; De Caria Paolo ; Antonio Natalello ; Martino Musati ; Luigi Chies

To determine the effects of dietary inclusion of bergamot pulp and olive leaves on pork quality, thirty-six barrows (Apulo-Calabrese; 112.5 ± 7.40 kg initial bodyweight) were randomly assigned to four experimental treatments and fed for 100 days a control diet (control group) or a diet similar to the control diet in which part of the cereals were replaced with 20 % (DM on the diet fed) of ensiled bergamot pulp (dry matter on the diet fed, EBP group) or olive leaves (OLL group) or a 1:1 mixture of both by-products (BPOL group). In the present study, the dietary administration of by-products did not influence the accumulation of IMF (P > 0.05) in meat. As for individual fatty acids, no differences were observed among groups. However, the dietary supplementation of bergamot pulp tended to increase (P = 0.073) the level of α-linolenic acid in meat. In raw and cooked meat TBARS values were higher (P < 0.001) in the Control group than in EBP, OLL and BPOL groups. The integration of 20 % of bergamot pulp and/or olive leaves by-products increased the levels of tocopherol and phenolic compounds in the diets, positively influencing the shelf life of meat. No effect of diet was observed on animal performance. The results of present study indicated mainly that partial replacement of cereals with 20 % DM on the diet fed of ensiled bergamot pulp and olive leaves, either alone or in combination, in the pig's diet led to greater oxidative stability of the meat.

2024-02-22·Scientific reports

α-lipoic acid modulates prostate cancer cell growth and bone cell differentiation.

Article

作者: K M Abdullah ; Gunjan Sharma ; Simran Takkar ; Jyoti B Kaushal ; Ramesh Pothuraju ; Bandana Chakravarti ; Surinder K Batra ; Jawed A Siddiqui

Prostate cancer (PCa) progression leads to bone modulation in approximately 70% of affected men. A nutraceutical, namely, α-lipoic acid (α-LA), is known for its potent anti-cancer properties towards various cancers and has been implicated in treating and promoting bone health. Our study aimed to explore the molecular mechanism behind the role of α-LA as therapeutics in preventing PCa and its associated bone modulation. Notably, α-LA treatment significantly reduced the cell viability, migration, and invasion of PCa cell lines in a dose-dependent manner. In addition, α-LA supplementation dramatically increased reactive oxygen species (ROS) levels and HIF-1α expression, which started the downstream molecular cascade and activated JNK/caspase-3 signaling pathway. Flow cytometry data revealed the arrest of the cell cycle in the S-phase, which has led to apoptosis of PCa cells. Furthermore, the results of ALP (Alkaline phosphatase) and TRAP (tartrate-resistant acid phosphatase) staining signifies that α-LA supplementation diminished the PCa-mediated differentiation of osteoblasts and osteoclasts, respectively, in the MC3T3-E1 and bone marrow macrophages (BMMs) cells. In summary, α-LA supplementation enhanced cellular apoptosis via increased ROS levels, HIF-1α expression, and JNK/caspase-3 signaling pathway in advanced human PCa cell lines. Also, the treatment of α-LA improved bone health by reducing PCa-mediated bone cell modulation.

项与硫辛酸相关的新闻（医药）

2024-04-03

·PRNewswire

Lipids with potential health benefits in herbal teas

Hokkaido University researchers have identified new lipids in some herbal teas in detail for the first time, preparing the ground for investigating their contribution to the health benefits of the teas. SAPPORO, Japan, April 3, 2024 /PRNewswire/ -- Herbal teas are enjoyed worldwide, not only for their taste and refreshment but also for a wide range of reputed health benefits. But the potential significance of a category of compounds called lipids in the teas has been relatively unexplored. Researchers at Hokkaido University, led by Associate Professor Siddabasave Gowda and Professor Shu-Ping Hui of the Faculty of Health Sciences, have now identified 341 different molecular species from five categories of lipids in samples of four types of herbal tea. They published their results in the journal Food Chemistry. Continue Reading The four types of herbal tea investigated in this study for their bioactive lipids. (Photo provided by Siddabasave Gowda) Lipids are a diverse collection of natural substances that share the property of being insoluble in water. They include all of the fats and oils that are common constituents of many foods, but they have generally not been examined as significant components of teas. The Hokkaido team selected four teas for their initial analysis: dokudami (Houttuynia cordata, fish mint), kumazasa (Sasa veitchii), sugina (Equisetum arvense, common horsetail) and yomogi (Artemisia princeps, Japanese mugwort). "These herbs are native to Japan and have been widely consumed as tea from ancient times due to their medicinal properties," says Gowda. The medicinal benefits attributed to these and other herbal teas include antioxidant, antiglycation, anti-inflammatory, antibacterial, antiviral, anti-allergic, anticarcinogenic, antithrombotic, vasodilatory, antimutagenic, and anti-aging effects. The lipids in the teas were separated and identified by combining two modern analytical techniques called high-performance liquid chromatography and linear ion trap-Orbitrap mass spectrometry. The analysis revealed significant variations in the lipids in the four types of tea, with each type containing some known bioactive lipids. These included a distinct category of lipids called short-chain fatty acid esters of hydroxy fatty acids (SFAHFAs), some of which had never previously been found in plants. SFAHFAs detected in tea could be a novel source of short-chain fatty acids, which are essential metabolites for maintaining gut health. "The discovery of these novel SFAHFAs opens new avenues for research," says Hui, adding that the lipid concentrations found in the teas are at levels that could be expected to have significant nutritional and medical effects in consumers. The lipids discovered also included α-linolenic acid, already known for its anti-inflammatory properties, and arachidonic acid which has been associated with a variety of health benefits. These two compounds are examples of a range of poly-unsaturated fatty acids found in the teas, a category of lipids that are well-known for their nutritional benefits. "Our initial study paves the way for further exploration of the role of lipids in herbal teas and their broad implications for human health and nutrition," Gowda concludes. "We now want to expand our research to characterize the lipids in more than 40 types of herbal tea in the near future." Contacts: Associate Professor Siddabasave Gowda Faculty of Health Sciences Graduate School of Global Food Resources Hokkaido University Tel: +81-11-706-3687 Email: [email protected] Professor Shu-Ping Hui Faculty of Health Sciences Hokkaido University Tel: +81-11-706-3693 Email: [email protected] Sohail Keegan Pinto (International Public Relations Specialist) Public Relations & Communications Division Office of Public Relations and Social Collaboration Hokkaido University Tel: +81-11-706-2186 Email: [email protected] Paper : Lipsa Rani Nath, et al. Dissecting new lipids and their composition in herbal tea using untargeted LC/MS. Food Chemistry. March 4, 2024 DOI: 10.1016/j.foodchem.2024.138941 Funding: This study was supported by the Japan Society for the Promotion of Science (JSPS; 22K1485002, 21H02376, 21K1481201); and the Japan Science and Technology Agency (JST) SPRING (JPMJSP2119). Press release on Hokkaido University website: Photo: SOURCE Hokkaido University

2024-03-11

·米内网

儿科中成药龙头发威！18个独家品种亮眼，4款1类新药、8个新品冲刺，发力1600亿市场

精彩内容亚宝药业是国内儿科中成药龙头之一，2023年预计实现归母净利润1.85亿元~2.15亿元，同比增长76.77%~105.44%。公司坚持“儿科第一”战略，以科技创新为引领，目前有4款1类新药在国内开展临床试验，涵盖3大千亿市场；仿制药方面，15个品种过评/视同过评，8个品种以新分类报产在审。18个独家品种亮眼！核心产品销售大涨亚宝药业主要从事药品的研发、生产和销售，现有产品涵盖中西药制剂、贴敷剂、原料药和药用包装材料等共计300多个品种，涉及儿科、止痛、心血管系统、内分泌系统、消化系统、清热解毒、精神神经、维生素矿物质等多个细分领域。1月20日，亚宝药业公告称，预计2023年公司实现归母净利润为1.85亿元~2.15亿元，与上年同期（法定披露数据）相比将增加76.77%~105.44%。亚宝药业表示，公司坚持“儿科第一”战略，集中优势资源，聚焦核心品种，加大市场开拓及推广力度，主营业务收入实现稳定增长，从而带动公司经营业绩实现较大增长。米内网数据显示，目前国内仅亚宝药业拥有生产批文的品种有18个（以药品名称计），包括14个中成药、4个化学药。14个中成药中，有6个为儿科用药，包括丁桂儿脐贴、薏芽健脾凝胶、儿童清咽解热口服液等。目前国内仅亚宝药业拥有生产批文的品种来源：米内网中国上市药品（MID）数据库OTC甲类产品丁桂儿脐贴为亚宝药业的独家专利产品，采用独特的纯中药外用脐疗方式，起到健脾温中、散寒止泻的功效，安全、有效、方便地治疗孩子腹泻、腹痛等症状。米内网数据显示，近年来中国零售药店终端（城市实体药店+网上药店）丁桂儿脐贴的销售额均达3亿元以上，2023年上半年超过2亿元，同比增长超过40%。在零售药店终端儿科止泻中成药产品排名中，丁桂儿脐贴连续多年稳居首位，市场占比均达90%以上。近年来中国零售药店终端丁桂儿脐贴销售情况（单位：万元）来源：米内网格局数据库随着核心产品的持续放量，亚宝药业在儿科用药领域的地位不断攀升。2023年上半年在中国城市实体药店终端、中国网上药店终端儿科中成药销售额TOP10厂家中，亚宝药业均名列前茅。在化药制剂方面，盐酸倍他司汀注射液为亚宝药业核心产品之一，这是一款H1受体激动剂，对心、脑血管有较明显的扩张作用，适用于内耳眩晕症，亦可用于脑动脉硬化、缺血性脑血管疾病及高血压所致体位性眩晕、耳鸣。米内网数据显示，近年来亚宝药业的盐酸倍他司汀注射液在中国城市公立医院、县级公立医院、城市社区中心以及乡镇卫生院（简称中国公立医疗机构）终端的销售额逐年上涨，2022年突破5亿元，2023上半年以46.6%的增速继续增长。目前尚无企业提交盐酸倍他司汀注射液一致性评价补充申请，也无企业的产品以新注册分类申报，短时间内不会被纳入国采。近年来中国公立医疗机构终端盐酸倍他司汀注射液（亚宝药业）销售情况来源：米内网中国公立医疗机构药品终端竞争格局1类新药猛攻3大千亿市场，首款生物药冲刺多年来，亚宝药业始终以传承中医药发展为己任，坚持以科技创新为引领，不断加大研发投入。据亚宝药业年报数据，2022年公司研发投入1.75亿元，占营收比重6.43%；2023前三季度研发费用超过8000万元（不含资本化投入）。在化药及生物药研发方面，目前亚宝药业已有4款1类新药在国内开展临床（不含暂停研发的品种），涉及2型糖尿病、急性脑卒中、脓毒症等适应症。米内网数据显示，2022年中国公立医疗机构终端消化及代谢系统药物、心脑血管疾病药物、全身用抗感染药物3个治疗大类的销售额分别超过1600亿元、1000亿元、1500亿元。亚宝药业正在开展临床的化药及生物药新药来源：米内网中国临床试验数据库SY-005注射液、SY-009胶囊均处于II期临床。SY-005注射液是一种创新型的重组蛋白，用于脓毒症的治疗，有望成为公司首款获批的生物药；SY-009胶囊为SGLT1抑制剂，目前国内暂无同靶点药物获批，亚宝药业还有另外一款同靶点在研药物已步入I期临床，为SY-008胶囊。此外，正在开展I期临床的注射用SY-007是一种新型干扰肽，可为脑卒中患者提供神经保护作用，降低脑卒中患者的缺血性脑损伤程度。目前国内暂无同靶点药物获批，亚宝药业走在研发前列。在中药新药研发方面，亚宝药业已布局了中药创新药、中药改良型新药、古代经典名方中药复方制剂等，涉及儿童急性上呼吸道感染、儿童咳嗽变异性哮喘、小儿湿疹、小儿肺热咳喘等适应症。15个品种过评，8个新品瞄准超90亿市场在仿制药方面，亚宝药业聚焦优势资源打造研发技术平台，重点关注高技术壁垒和具有成本优势的高端仿制药产品研发。目前公司已初步建立透皮贴剂、复杂注射剂、外用软膏剂、缓控释制剂等高难度制剂技术平台，并顺利推进管线内产品研发。米内网数据显示，目前亚宝药业有15个品种过评/视同过评，涵盖心脑血管系统、消化及代谢系统、血液和造血系统、抗感染等多个治疗领域。其中，苯甲酸阿格列汀片为首仿+首家过评，硫辛酸片为独家过评。亚宝药业过评情况注：带*为首家/独家过评，加粗为国采中选来源：米内网一致性评价进度数据库在已开展的九批十轮集采中，亚宝药业有3个品种顺利中选，分别为硫辛酸注射液、胞磷胆碱钠注射液及甲钴胺注射液。公司已过评品种中，尚有3个品种暂未纳入国采，其中苯甲酸阿格列汀片已满足5家及以上的充分竞争条件，但该产品尚在专利期内，预计不会纳入第十批集采。此外，亚宝药业还有8个品种（以药品名称计）按新注册分类报产在审（不含联合申报及非制剂产品），以消化系统及代谢药为主。若以通用名计，则上述药品2022年在中国公立医疗机构终端的销售额合计超过90亿元，包括硝苯地平、间苯三酚等临床畅销大品种。亚宝药业新分类报产且在审的品种（不含联合申报）来源：米内网中国申报进度（MED）数据库注：米内网《中国三大终端六大市场药品竞争格局》，统计范围是：城市公立医院和县级公立医院、城市社区中心和乡镇卫生院、城市实体药店和网上药店，不含民营医院、私人诊所、村卫生室，不含县乡村药店；上述销售额以产品在终端的平均零售价计算。数据统计截至3月8日，如有疏漏，欢迎指正！本文为原创稿件，转载请注明来源和作者，否则将追究侵权责任。投稿及报料请发邮件到872470254@qq.com稿件要求详询米内微信首页菜单栏商务及内容合作可联系QQ：412539092【分享、点赞、在看】点一点不失联哦

财报

2024-02-15

·PRNewswire

Embrace Heart Health and the Power of Walnuts During American Heart Month

New survey finds most Americans aren't eating enough walnuts to reap their heart health benefits FOLSOM, Calif., Feb. 15, 2024 /PRNewswire/ -- A new survey1 from California Walnuts just revealed that only one-fifth of Americans (19%) say they eat enough walnuts to support a diet for heart health. With their exceptional nutritional profile, Americans are missing out on a delicious and easy way to support a healthy heart. Heart disease remains the leading cause of death in the U.S.,2 but research has shown that simple dietary changes can have a significant impact on heart health. In recognition of American Heart Month, California Walnuts encourages Americans to embrace heart health by including walnuts in their daily diet. Over the past three decades, studies have demonstrated the cardiovascular benefits of walnuts, exploring how eating walnuts affects various factors related to heart health such as cholesterol, blood pressure, inflammation and blood vessel function. Not only do walnuts help maintain healthy cholesterol levels,3,4 but they are also a versatile, plant-based whole food that makes a delicious addition to any meal. Whether enjoyed in salads, main dishes or snacks, walnuts provide a buttery richness and satisfying texture. According to a nationally representative survey of U.S. adults1, three in five respondents (62%) say walnuts pair best with salads, followed by half (47%) saying dark chocolate pairs well with walnuts, creating a craveable, heart-smart snack combo. One ounce of walnuts is a powerhouse of important nutrients for optimal health, including 4 grams of protein and 2 grams of fiber. Walnuts are also the only tree nut that is an excellent source of the plant-based omega-3 alpha-linolenic acid (2.5g/oz), an essential fatty acid that may play a role in heart health.5,6 An easy way to estimate how much is the right daily serving of walnuts is to simply grab a handful (~1 oz). "Following a diet that supports heart health is important year-round and choosing foods, like walnuts, is a fundamental habit to build," said California Walnuts partner, Samantha Cassetty, MS, RD. "From salads and oatmeal to baked goods, walnuts enhance the taste of everyday favorites while offering numerous potential health benefits." To help incorporate more walnuts into your diet, Cassetty suggests the following: Eat a handful of walnuts every day. You don't even need to eat them in one sitting. You could toss a few into your morning oatmeal or yogurt at breakfast, add some to roasted veggies or salad dishes at lunch, crush them to use as a breading for fish or chicken at dinner, and include them into desserts. Incorporate more whole, plant-based foods. Many simple ways exist for incorporating whole, plant-based options like walnuts, oats, quinoa, fruits, vegetables and seeds into your everyday diet. While stocking your refrigerator with fruits and vegetables, don't forget walnuts. They are nutritious while also being versatile and great tasting. Limit your intake of added sugars. To promote heart health, it is important to limit your intake of added sugars as they can raise triglyceride levels and promote inflammation, which both contribute to heart disease. Desserts are often a major source of added sugar in our diets, so it's beneficial to explore more nutritious options, like Walnut Stuffed Chocolate Covered Dates or No-Bake Walnut, Cocoa, Cherry Bars. Visit walnuts.org/american-heart-month for heart-healthy recipe ideas, tips for maintaining freshness and more information about walnuts and heart health. About the California Walnut Board The California Walnut Board (CWB) was established in 1948 to represent the walnut growers and handlers of California. The CWB is funded by mandatory assessments of the handlers. The CWB is governed by a Federal Walnut Marketing Order. The CWB promotes usage of walnuts in the United States through publicity and educational programs. The CWB also provides funding for walnut production, food safety and post-harvest research. References: 1. The California Walnut Commission conducted an online survey of 1,000 U.S. adults, ages 18+ in January 2024. The survey was conducted at a 95% confidence level with a +/-3% margin of error. 2.Tsao, C. et al. Heart Disease and Stroke Statistics—2023 Update: A Report From the American Heart Association. Circulation. 2023;147:e93–e621. 3. FDA approved claim: Supportive but not conclusive research shows that eating 1.5 ounces of walnuts per day, as part of a low saturated fat and low cholesterol diet, and not resulting in increased caloric intake, may reduce the risk of coronary heart disease. U.S. Food and Drug Administration, March 2004. One ounce of walnuts provides 18g of total fat, 2.5g of monounsaturated fat, 13g of polyunsaturated fat, including 2.5g of alpha-linolenic acid, the plant-based omega-3. 4. Kris-Etherton P. Walnuts decrease risk of cardiovascular disease: a summary of efficacy and biologic mechanisms. J Nutr. 2014; 10: 39:2S-8S. 5. U.S. Department of Agriculture, Agricultural Research Service. FoodData Central, 2019. fdc.nal.usda.gov. 6. Sala-Vila A, Fleming J, Kris-Etherton P, Ros E. Impact of α-Linolenic Acid, the Vegetable ω-3 Fatty Acid, on Cardiovascular Disease and Cognition. Adv Nutr. 2022 Oct 2;13(5):1584-1602. doi: 10.1093/advances/nmac016. PMID: 35170723; PMCID: PMC9526859. SOURCE California Walnut Commission

AHA会议

100 项与硫辛酸相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	硫辛酸	A10B	DB00166

研发状态

适应症	最高研发状态	国家/地区	公司
糖尿病性神经病变	批准上市	韩国更多	Bukwang Pharmaceutical Co., Ltd. 更多
脓毒症	临床3期	埃及更多	Ain Shams University 更多
寻常痤疮	临床2期	中国更多	上海复旦张江生物医药股份有限公司更多
糖尿病	无进展	中国更多	诺凡麦医药有限公司更多

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


ISRCTN13159380 (Pubmed \| Oxid Med Cell Longev)	临床2/3期	2型糖尿病	135	Experimental group (600 mg/day ALA)	觸簾觸遞膚齋構餘鬱製(積繭醖範築製襯壓鏇鑰) = 膚願淵觸壓憲範鹽鬱觸廠夢膚範積鹹齋鑰窪願 (壓觸製鏇鏇遞鏇壓醖範 )	-	2019-01-01
				Alpha-lipoic Acid (Placebo group)	觸簾觸遞膚齋構餘鬱製(積繭醖範築製襯壓鏇鑰) = 鏇壓製範鑰糧願簾衊築廠夢膚範積鹹齋鑰窪願 (壓觸製鏇鏇遞鏇壓醖範 )
P1.373 (AAN2016)	N/A	继发进展型多发性硬化	54	Lipoic acid 1200mg	繭鹽糧獵鏇構遞鑰淵觸(製衊衊襯餘膚衊製願廠) = 21 糧範廠構衊廠膚鏇顧夢 (膚鬱鏇淵網積廠齋衊夢 ) 更多	-	2016-04-05
NCT02439879 (Pubmed \| J Diabetes Res)	临床4期	2型糖尿病伴有周围神经病	45	ALA (600 mg qd)	繭膚觸鹹築製範淵醖蓋(窪衊淵範鹽齋憲鹹鹹製) = 壓夢窪蓋衊蓋製夢齋獵鹹夢衊窪觸積遞蓋膚選 (憲窪遞願襯憲壓壓夢積 )	-	2015-01-01
NCT01188811 (Pubmed \| Neurol Neuroimmunol Neuroinflamm)	临床2/3期	继发进展型多发性硬化	54	Lipoic acid 1,200 mg	- 更多	积极	2017-09-01
				Placebo
Pubmed	N/A	多囊卵巢综合征	6	Controlled-release alpha lipoic acid (CRLA)	鹹餘衊簾網襯選鑰齋選(鑰夢壓蓋鹹衊獵廠醖遞) = toward the larger, more buoyant LDL subclass fraction 鑰觸鹽膚觸憲艱築製鏇 (獵膚窪鑰憲遞鑰遞餘鹽 )	积极	2010-03-01
Pubmed	临床4期	胰岛素抵抗	32	ALA 400 mg b.i.d.	窪觸顧蓋積築築製繭鹽(獵糧醖觸艱膚壓網繭壓) = 獵鬱製糧襯顧壓觸夢齋襯築構選餘餘遞觸積鹹 (範顧蓋夢築糧憲壓夢壓, 0.36 ~ 0.70)	-	2018-03-01
ESPE2014	N/A	1型糖尿病	-	Anti-oxidant diet 10,000 ORAC+α-lipoic acid	(窪網餘積蓋鑰積齋襯簾) = 襯襯繭齋衊淵願夢鬱廠構糧網觸選繭製憲鹹鹽 (艱鏇蓋淵獵蓋網蓋廠繭 ) 更多	-	2014-09-18
				Alpha-Lipoic Acid	(窪網餘積蓋鑰積齋襯簾) = 壓遞構觸襯淵鑰艱網鹽構糧網觸選繭製憲鹹鹽 (艱鏇蓋淵獵蓋網蓋廠繭 ) 更多
2018 ARVO Annual Meeting (ARVO2018)	N/A	interleukin (IL) \| interferon (IFN) \| tumor necrosis factor (TNF)	-	Hyaluronic acid	(網鏇鹹顧觸構網鏇獵襯) = 鬱憲蓋鏇觸鹽齋築衊衊鑰遞網襯廠衊壓構鏇願 (窪積襯鹽壓餘糧艱鏇鹹 )	-	2018-07-01
				Lipoic acid	(網鏇鹹顧觸構網鏇獵襯) = 顧襯製壓積憲繭願願壓鑰遞網襯廠衊壓構鏇願 (窪積襯鹽壓餘糧艱鏇鹹 )
ASCO2016	N/A	三阴性乳腺癌	1	Nivolumab + Ipilimumab + Hyperthermia + Vitamin-C + Alpha Lipoic Acid + Cyclophosphamide + HD IL-2	襯觸觸蓋廠糧製製鏇選(艱齋艱願窪繭衊鏇壓醖) = 觸觸鑰鹹醖夢繭襯顧鑰蓋鏇遞鏇選繭齋願蓋淵 (艱選餘鏇淵膚獵餘蓋遞 )	积极	2016-05-20
ESPE2018	N/A	代谢综合征	44	α-lipoic acid	(壓憲膚積鹹築膚糧蓋獵) = There is no side effect of α-lipoic acid in children 鬱淵構顧構製鹽衊鏇願 (鑰簾網糧鹹簾淵淵鹹構 )	积极	2018-09-27
				Alpha-lipoic Acid